MindMed update on major depressive disorder data: Rob Barrow, CEO

MindMed update on major depressive disorder data: Rob Barrow, CEO

MindMed — 3 videos in collection

More on this equity

MindMed is a clinical-stage US biopharmaceutical company aiming to leverage psychedelic medicines to target life-debilitating mental health conditions such as anxiety, ADHD and autism. Its most advanced clinical programmes are investigating the use of LSD D-tartrate (MM-120) for treating generalised anxiety disorder (GAD) and attention-deficit hyperactivity disorder (ADHD). The Phase IIb GAD trial is a randomised dose-finding study that will recruit up to 200 patients and is expected to deliver top-line results in H223. The Phase IIa proof-of-concept study in ADHD will assess the safety and efficacy of low-dose MM-120 as treatment for ADHD in adults, with readouts anticipated in H223. Additionally, the company will initiate a Phase I study in 2023 investigating R-MDMA for treating autism spectrum disorder. MindMed is also looking to use digital platforms to provide scalable, accessible and safe psychedelic treatment solutions to patients, overcoming resourcing constraints faced by healthcare providers and promoting adoption.

In this video, Rob Barrow, MindMed Chief Executive Officer, provides an update on the recently released positive phase II top-line data addressing major depressive disorder.

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free